BMJ  2003;327:807 (4 October), doi:10.1136/bmj.327.7418.807-a

Letter

"Polypill" to fight cardiovascular disease

Now who's playing God?

The first 150 words of the full text of this article appear below.

EDITOR—The implications of Wald and Law's paper are truly monumental.1 Although they are scientifically brilliant and Nobelian in their relevance, they are simultaneously unsettling and alarming.

The impact of such a low cost initiative on individual and population based health parameters is potentially enormous. But having, at a stroke (to coin a phrase), slashed the risk of cardiovascular disease—what then for humanity? Will everyone be that much healthier, happier, and productive in his or her life?

As general practitioners, we have many patients nowadays whose cardiovascular problems have been managed by controlling their blood pressure, reducing their low density lipoprotein cholesterol concentration, and taking aspirin. Yet they continue to get older and develop other problems—often of a serious, debilitating, and long term nature.

Having "lost" the cardiovascular market to the low cost generic "Polypill," pharmaceutical companies will surely then concentrate their efforts on other avenues. So is it . . . [Full text of this article]

Steve Taylor, partner

steve@dox.co.nz

Angela Konings, partner

Sunset Road Family Doctors, 14/326 Sunset Rd, Mairangi Bay, Auckland 1310, New Zealand


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Polypill may be available in two years
Richard Smith
BMJ 2003 327: 0. [Extract] [Full Text] [PDF]

A strategy to reduce cardiovascular disease by more than 80%
N J Wald and M R Law
BMJ 2003 326: 1419. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Stirban, A. O., Tschoepe, D. (2008). Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care 31: S226-S228 [Abstract] [Full text]  



Access jobs at BMJ Careers
Whats new online at Student 

BMJ